Secret Goldman Team Sidesteps Volcker After Blankfein Vow – Bloomberg 01-07-13

Salient to Investors: Goldman Sachs’ Multi-Strategy Investing team’s survival shows how Goldman Sachs has worked around regulations curbing proprietary bets at banks. Matthew Richardson at NYU said the law does not bar longer-term wagers so leaves room for other risky investments. Richardson said from a systemic-risk perspective, it’s longer-term holdings which are

READ MORE...

Almost All of Wall Street Got 2012 Market Calls Wrong – Bloomberg 01-04-13

Salient to Investors: John Paulson said the euro would fall apart and bet against the region’s debt. Morgan Stanley predicted the S&P 500 would lose 7 percent and Credit Suisse predicted wider swings in equity prices. Warren Buffett called bonds dangerous. The largest banks and most-successful investors failed to anticipate how government actions would influence

READ MORE...

Carson Block Goes Short Unafraid as Chinese Gangsters Chase – Bloomberg 12-10-12

Salient to Investors: Carson Block at Muddy Waters said he stopped betting against Chinese companies this year after government agents hindered his analysts and harassed workers at his storage company in Shanghai. Block says China is protecting frauds by making it difficult to research short sale candidates, and has used intelligence and police agencies to deter

READ MORE...

Diamond, Dimon’s Early Risks Made Them Better: Adoboli – Bloomberg 11-22-12

Salient to Investors: Kweku Adoboli, the former UBS trader jailed over losing $2.3 billion, said: Financial leaders such as Jamie Dimon, Bob Diamond and Yassine Bouhara all lost large amounts of money at some point in their careers. (Bloomberg couldn’t couldn’t confirm whether they had substantial losses earlier in their careers.) The more senior you are

READ MORE...

Insider Mulls Suicide as Health Care Tipping Wave Grows – Bloomberg 11-12-12

Salient to Investors: Markets are awash in insider trading, and healthcare has been particularly hard-hit since it offers illegal traders more opportunities to profit than the finance and technology sectors. Health companies can live or die on the results of drug trials and the industry has undergone significant consolidation. What’s notable about

READ MORE...